Talon Resources Targets Ontario Gold Growth After AIM Move and Eagle Lake Acquisition, CEO Says.Watch here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksEden Research Regulatory News (EDEN)

Share Price Information for Eden Research (EDEN)

Share Price is delayed by 15 minutes
Get Live Data
3.00    0.00 (0.00%)
Bid:
2.90
Ask:
3.10
Spread: 0.20 (6.897%)
Market Cap: £24.10m
EDEN Live PriceLast checked at - London Stock Exchange

Intraday Eden Research Share Chart

Australian Patent Expansion

27 Nov 2012 07:00

RNS Number : 0441S
Eden Research plc
27 November 2012
 



 

 

EDEN RESEARCH PLC

("Eden" or "Company")

 

Second Notice of Acceptance expands patent protection in Australia

 

Eden Research plc, the agrochemical and encapsulation development company, announces that it has received a second Notice of Acceptance from the Commonwealth of Australia Patent Office for one of its composition patents based on its base terpene components and encapsulation technology.

 

This patent covers the use of the Company's core technology as part of a composition which in this case is effective in controlling fungal and bacterial plant pathogens (the first Notice of Acceptance, as announced on 9 November 2012, was for flying insects and arachnids). The patent is relevant to agrochemical applications of Eden's technology, particularly in providing a safe, effective and environmentally friendly alternative to existing chemical pesticides used to protect vegetables, orchards and glasshouse crops.

 

The Patent, number 2006321416, which expires in 2026, covers a number of applications within the plant disease and bacteria sector.

 

Clive Newitt, Managing Director of Eden said, "Each time we receive a notification of either the grant of, or notice of acceptance of, a patent, it further strengthens our patent portfolio and, as we are in the business of licensing intellectual property rights, these events are of great significance. This particular event is important as the pesticide market in Australia is estimated to be a US$ 2.6 billion market* and since the scope of the patent is wide it is of significant value to us."

 

*according to 2011 Australian Pesticides and Veterinary Medicines Authority estimates

 

Eden Research plc

www.edenresearch.com

Clive Newitt, Managing Director

Tel: 01993 862 761

Alex Abrey, Chief Financial Officer

Zeus Capital Limited

Ross Andrews, Andrew Jones (nomad)

John Goold (Institutional Sales)

Tel: 0161 831 1512

Tel: 020 716 8925

Walbrook PR Ltd

Tel: 020 7933 8780

Paul McManus (Media Relations)

Mob: 07980 541 893 or paul.mcmanus@walbrookpr.com

Paul Cornelius (Investor Relations)

Mob: 07827 879 460 or paul.cornelius@walbrookir.com

 

 

 

Notes:

 

Eden has developed a terpene-based encapsulation technology which uses yeast cells to deliver a slow release of natural compounds for agricultural and non-agricultural uses.

 

Terpenes are natural compounds which function as defence mechanisms in many plant groups and are released in response to infection, attack by pests, stress or mechanical injury. Terpenes are already widely used in the food flavouring, cosmetic and pharmaceutical industries.

 

Historically, terpenes have had limited commercial use in the agrochemical sector due to their volatility, phytotoxicity and poor solubility. Eden's platform encapsulation technology provides a unique, environmentally friendly solution to these problems and enables terpenes to be used as effective, low-risk agrochemicals.

 

The next-generation encapsulation technology, licensed from University of Massachusetts Medical School ("UMMS") recently, provides significant additional benefits to the original system as it allows release to be controlled by environmental factors rather than relying solely upon the chemistry of the substances used. This means that there is more control over the timing of the release of the active compound being carried allowing for further reduction in chemicals applied whilst ensuring maximum effectiveness.

 

The UMMS license also significantly expands the potential use of the Eden technology in non-agricultural applications such as health and beauty, cosmetics and animal health.

 

For more information about Eden, please visit www.edenresearch.com

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCLLFIDLTLRFIF
Date   Source Headline
27th May 20267:00 amRNSDirectorate change
28th Apr 20267:00 amRNSTrading Update
16th Apr 20262:59 pmRNSHolding(s) in Company
14th Apr 20264:30 pmRNSHolding(s) in Company
14th Apr 20263:31 pmRNSHolding(s) in Company
13th Apr 202611:31 amRNSHolding(s) in Company
10th Apr 20267:00 amRNSCompletion of Conditional Placing and TVR
8th Apr 202612:10 pmRNSSatisfaction of Conditions of Conditional Placing
2nd Apr 20267:00 amRNSThymolflex EPA approval
19th Feb 20263:59 pmRNSHolding(s) in Company
19th Feb 20261:29 pmRNSHolding(s) in Company
18th Feb 20269:40 amRNSResult of General Meeting and Total Voting Rights
5th Feb 20262:50 pmRNSResult of Retail Offer
2nd Feb 20261:01 pmRNSLaunch of Retail Offer
2nd Feb 202612:57 pmRNSProposed Placing and Subscription
9th Jan 20267:00 amRNSNovellus+ Regulatory Authorisation in Chile
7th Jan 20267:00 amRNSMevalone Label Extension in France
18th Dec 20257:00 amRNSAppointment of Syngenta as Distribution Partner
20th Nov 20257:00 amRNS3LOGY Label Extension in Italy
17th Nov 20257:00 amRNSEcovelex 2025 Approval in Italy
17th Sep 20259:45 amRNSDirector/PDMR Shareholdings
17th Sep 20258:36 amRNSDirector/PDMR Shareholdings
17th Sep 20257:00 amRNSHalf Yearly Report
15th Sep 20257:00 amRNSNotice of Results
18th Jun 20251:40 pmRNSResult of AGM
18th Jun 20257:00 amRNSAGM Statement
16th Jun 20257:00 amRNSEcovelex Partnership with Royal Holloway
27th May 20255:22 pmRNSNotice of AGM
13th May 20257:00 amRNSMevalone Approval in California - Powdery Mildew
9th May 20257:00 amRNS-RInvestor Presentation via Investor Meet Company
6th May 202512:08 pmRNSHolding(s) in Company
6th May 20257:00 amRNSPreliminary results for the year ended 31 Dec 2024
10th Apr 20257:00 amRNSThymol Supply Agreement For Bee Health
1st Apr 202510:08 amRNSDirector/PDMR Shareholdings
24th Mar 20257:00 amRNSAppointment of Distribution Partner in Kenya
10th Mar 20257:00 amRNSAppointment of Joint Broker
5th Mar 202512:52 pmRNSDirector/PDMR Shareholding
5th Mar 20257:00 amRNSDirector/PDMR Shareholding
4th Mar 20252:13 pmRNSDirector/PDMR Shareholdings
6th Feb 20252:08 pmRNSDirector/PDMR Shareholding
5th Feb 20257:00 amRNS-RInvestor Presentation via Investor Meet Company
28th Jan 202510:36 amRNSDirector/PDMR Shareholdings
13th Jan 20257:12 amRNSTrading Update
20th Dec 20247:00 amRNSRegulatory approval for Novellus+ in Mexico
16th Dec 20247:00 amRNSAppointment of Distributor in Austria
11th Dec 20247:00 amRNSMevalone Organic Input Registration in Germany
7th Nov 20247:01 amRNSTrading Update
7th Nov 20247:00 amRNSEcovelex Approval in Italy
8th Oct 202411:24 amRNSOTCQB exchange update
23rd Sep 20247:00 amRNSHalf yearly Report

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.